231 related articles for article (PubMed ID: 19033566)
1. Adjuvant chemoradiation for pancreatic cancer: few good data, much debate.
Twombly R
J Natl Cancer Inst; 2008 Dec; 100(23):1670-1. PubMed ID: 19033566
[No Abstract] [Full Text] [Related]
2. The recent past and future of adjuvant therapy for pancreatic cancer.
Yeo CJ
Ann Surg Oncol; 2003 Jun; 10(5):488-9. PubMed ID: 12794012
[No Abstract] [Full Text] [Related]
3. [Chemoradiation for pancreatic adenocarcinoma].
Flandin I; Mornex F; Claude L; Kubas A; Khodri M; Wautot V; Mazeron R; Partensky C
Cancer Radiother; 2004 Nov; 8 Suppl 1():S80-7. PubMed ID: 15679252
[TBL] [Abstract][Full Text] [Related]
4. Survival for patients with pancreatic cancer after addition of gemcitabine to fluorouracil chemoradiation.
Vikram B
JAMA; 2008 Jun; 299(24):2852; author reply 2852-3. PubMed ID: 18577724
[No Abstract] [Full Text] [Related]
5. Survival for patients with pancreatic cancer after addition of gemcitabine to Fluorouracil chemoradiation.
Fujita T
JAMA; 2008 Jun; 299(24):2852; author reply 2852-3. PubMed ID: 18577725
[No Abstract] [Full Text] [Related]
6. Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
Cunningham SC; Cusnir M; Burdick RK; Van Echo DA; Moesinger R
Clin Adv Hematol Oncol; 2003 Dec; 1(12):741-2; discussion 743. PubMed ID: 16258479
[No Abstract] [Full Text] [Related]
7. The case for routine use of adjuvant therapy in pancreatic cancer.
Kennedy EP; Yeo CJ
J Surg Oncol; 2007 Jun; 95(7):597-603. PubMed ID: 17230543
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
Breslin TM; Hess KR; Harbison DB; Jean ME; Cleary KR; Dackiw AP; Wolff RA; Abbruzzese JL; Janjan NA; Crane CH; Vauthey JN; Lee JE; Pisters PW; Evans DB
Ann Surg Oncol; 2001 Mar; 8(2):123-32. PubMed ID: 11258776
[TBL] [Abstract][Full Text] [Related]
9. [Chemoradiation in pancreatic carcinoma].
Claude L; Mornex F
Cancer Radiother; 2003 Aug; 7(4):254-65. PubMed ID: 12914858
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant and adjuvant strategies for pancreatic cancer.
Ghaneh P; Smith R; Tudor-Smith C; Raraty M; Neoptolemos JP
Eur J Surg Oncol; 2008 Mar; 34(3):297-305. PubMed ID: 17936564
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas.
Kachnic LA; Shaw JE; Manning MA; Lauve AD; Neifeld JP
Int J Cancer; 2001 Apr; 96(2):132-9. PubMed ID: 11291097
[TBL] [Abstract][Full Text] [Related]
12. Preoperative chemoradiation therapy for adenocarcinoma of the pancreas: The Fox Chase Cancer Center experience, 1986-2003.
Meszoely IM; Wang H; Hoffman JP
Surg Oncol Clin N Am; 2004 Oct; 13(4):685-96, x. PubMed ID: 15350942
[TBL] [Abstract][Full Text] [Related]
13. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Regine WF; Winter KA; Abrams R; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Rich TA; Willett CG
Ann Surg Oncol; 2011 May; 18(5):1319-26. PubMed ID: 21499862
[TBL] [Abstract][Full Text] [Related]
14. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial).
Maurel J; Sánchez-Cabús S; Laquente B; Gaba L; Visa L; Fabregat J; Povés I; Roselló S; Díaz-Beveridge R; Martín-Richard M; Rodriguez J; Sabater L; Conill C; Cambray M; Reig A; Ayuso JR; Valls C; Ferrández A; Bombí JA; Ginés A; García-Albéniz X; Fernández-Cruz L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):935-943. PubMed ID: 30225601
[TBL] [Abstract][Full Text] [Related]
15. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas.
White R; Lee C; Anscher M; Gottfried M; Wolff R; Keogan M; Pappas T; Hurwitz H; Tyler D
Ann Surg Oncol; 1999; 6(1):38-45. PubMed ID: 10030414
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer.
Martenson JA; Vigliotti AP; Pitot HC; Geeraerts LH; Sargent DJ; Haddock MG; Ghosh C; Keppen MD; Fitch TR; Goldberg RM
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1305-10. PubMed ID: 12654442
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
Landry J; Catalano PJ; Staley C; Harris W; Hoffman J; Talamonti M; Xu N; Cooper H; Benson AB
J Surg Oncol; 2010 Jun; 101(7):587-92. PubMed ID: 20461765
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of twenty patients with adenocarcinoma of the pancreas: resection following combined modality therapy.
Cooperman AM; Snady H; Bruckner HW; Hammerman H; Siegel J; Stark B; Bank S
Surg Clin North Am; 2001 Jun; 81(3):699-708. PubMed ID: 11459283
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer.
Desai S; Ben-Josef E; Griffith KA; Simeone D; Greenson JK; Francis IR; Hampton J; Colletti L; Chang AE; Lawrence TS; Zalupski MM
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1450-5. PubMed ID: 19409732
[TBL] [Abstract][Full Text] [Related]
20. Real-world impact of availability of adjuvant therapy on outcomes in patients with resected pancreatic adenocarcinoma: a Canadian Cancer Agency experience.
Kim C; Owen D; Gill S
Am J Clin Oncol; 2012 Jun; 35(3):212-5. PubMed ID: 21358297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]